Last update Aug. 24, 2014

Пазопаниба Гидрохлорид

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Inhibitor of BCR-ABL and SRC tyrosine kinase that is used for treatment of several neoplastic diseases.

At latest update, relevant published data on excretion into breast milk were not found.

Because of high serum protein-binding capacity, excretion into breast milk in significant amount is seemingly unlikely.

If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, it should be wait for 10 half-lives (T ½).

It means that 13 days should be waited before resuming breastfeeding.

Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.

Alternatives

We do not have alternatives for Пазопаниба Гидрохлорид.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Пазопаниба Гидрохлорид is also known as Pazopanib. Here it is a list of alternative known names::


Group

Пазопаниба Гидрохлорид belongs to this group or family:

Tradenames

Main tradenames from several countries containing Пазопаниба Гидрохлорид in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 14 - 39 %
Molecular weight 474 daltons
Protein Binding > 99 %
Tmax 2 - 4 hours
T½ 31 hours

References

  1. PDR.net. Pazopanib. Drug Summary. 2014 Full text (link to original source) Full text (in our servers)
  2. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 Abstract
  3. EMEA. Pazopanib. Ficha técnica. 2012 Full text (in our servers)
  4. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011 Abstract

Total visits

1,707

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM